Avidity Biosciences Inc [RNA] stock prices are down -1.53% to $29.58 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RNA shares have gain 3.57% over the last week, with a monthly amount drifted -15.29%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Avidity Biosciences Inc [NASDAQ: RNA] stock has seen the most recent analyst activity on March 07, 2025, when Scotiabank initiated its Sector Outperform rating and assigned the stock a price target of $70. Previously, H.C. Wainwright started tracking the stock with Buy rating on December 20, 2024, and set its price target to $72. On November 26, 2024, RBC Capital Mkts initiated with a Outperform rating and assigned a price target of $67 on the stock. Goldman started tracking the stock assigning a Buy rating and suggested a price target of $59 on September 24, 2024. Barclays initiated its recommendation with a Overweight and recommended $63 as its price target on August 28, 2024. BofA Securities started tracking with a Buy rating for this stock on May 03, 2024, and assigned it a price target of $40. In a note dated March 14, 2024, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $60 on this stock.
The stock price of Avidity Biosciences Inc [RNA] has been fluctuating between $20.80 and $56.00 over the past year. Currently, Wall Street analysts expect the stock to reach $59 within the next 12 months. Avidity Biosciences Inc [NASDAQ: RNA] shares were valued at $29.58 at the most recent close of the market. An investor can expect a potential return of 99.46% based on the average RNA price forecast.
Analyzing the RNA fundamentals
The Avidity Biosciences Inc [NASDAQ:RNA] reported sales of 10.90M for trailing twelve months, representing a surge of 35.57%. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at -34.77%, Pretax Profit Margin comes in at -29.58%, and Net Profit Margin reading is -29.58%. To continue investigating profitability, this company’s Return on Assets is posted at -0.21, Equity is -0.26 and Total Capital is -0.26. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 28.81 points at the first support level, and at 28.05 for the second support level. However, for the 1st resistance point, the stock is sitting at 30.45, and for the 2nd resistance point, it is at 31.33.
Ratios To Look Out For
It’s worth pointing out that Avidity Biosciences Inc [NASDAQ:RNA]’s Current Ratio is 15.73. In addition, the Quick Ratio stands at 15.73 and the Cash Ratio stands at 2.24. Considering the valuation of this stock, the price to sales ratio is 326.23, the price to book ratio is 2.49.
Transactions by insiders
Recent insider trading involved WILLIAM MICHAEL FLANAGAN, Officer, that happened on Mar 11 ’25 when 20000.0 shares were purchased. Chief Program Officer, Gallagher Kathleen P. completed a deal on Mar 03 ’25 to sell 5875.0 shares. Meanwhile, Chief Program Officer Gallagher Kathleen P. sold 5875.0 shares on Feb 03 ’25.
